Search results for "area under the curve"

showing 10 items of 140 documents

A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types

2020

The purpose of this study is to clinically validate a series of circulating miRNAs that distinguish between the 4 most prevalent tumor types (lung cancer (LC)

OncologyMaleLung NeoplasmsColorectal cancerlcsh:ChemistryProstate cancer0302 clinical medicinelcsh:QH301-705.5SpectroscopyEarly Detection of CancerAged 80 and over0303 health sciencesArea under the curveGeneral MedicineMiddle AgedEarly diagnosisprostate cancer3. Good healthComputer Science Applications030220 oncology & carcinogenesisArea Under CurveFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyBreast Neoplasmscolorectal cancerCatalysisArticleInorganic Chemistry03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineHumansCirculating MicroRNAPhysical and Theoretical ChemistryLung cancerMolecular Biology030304 developmental biologyAgedNeoplasm StagingReceiver operating characteristicbusiness.industryOrganic ChemistryCancerProstatic Neoplasmsmedicine.diseaseCirculating MicroRNAlung cancerlcsh:Biology (General)lcsh:QD1-999ROC CurveCase-Control StudiesMultivariate Analysiscirculating microRNAsbusinessInternational Journal of Molecular Sciences
researchProduct

Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STE…

2011

Introduction: Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence. Methods: Patients with extensive SCLC, age >70 years, and performance status 0-2 were eligible for a study looking for optimal two-drug combination of gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car). Gemcitabine dose was the same (1000 mg/m2, days 1-8) in all combinations. A two-stage minimax flexible design for response was applied to GemVin combination (Vin 25 mg/m2, days 1-8). For GemCar, GemCis, GemEto, a phase I-II Bayesian design was applied, looking for the optimal dose of the partner drugs. Objective response rate ≥60% and un…

OncologyMaleLung NeoplasmsDeoxycytidineCarboplatinchemistry.chemical_compoundElderlyAntineoplastic Combined Chemotherapy Protocols80 and overCarcinoma Small CellMultivariate AnalysiEtoposideEtoposidePlatinum compoundsAged 80 and overArea under the curveSCLCVinorelbinePrognosisElderly; Etoposide; Gemcitabine; Platinum compounds; SCLC; Vinorelbine; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Small Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; VinorelbineTreatment OutcomeOncologyPlatinum compoundToxicityFemalemedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiVinorelbineVinblastineDisease-Free SurvivalInternal medicinemedicineHumansAgedProportional Hazards ModelsCisplatinAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryCarcinomaSmall CellGemcitabineGemcitabineCarboplatinSurgeryLung NeoplasmchemistryMultivariate AnalysisProportional Hazards ModelQuality of LifeCisplatinbusiness
researchProduct

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

2011

Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease.We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease. Outcome measures included progression-free survival, first analyzed per protocol and then updated, and interim overall survi…

Oncologymedicine.medical_specialtyBevacizumabCyclophosphamidePaclitaxelMedizinAngiogenesis InhibitorsCarcinoma Ovarian EpithelialAntibodies Monoclonal HumanizedDisease-Free SurvivalCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsCarcinomaMedicineHumansNeoplasms Glandular and EpithelialSurvival analysis030304 developmental biologyGynecologyOvarian Neoplasms0303 health sciencesbusiness.industryArea under the curveGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapySurvival AnalysisCarboplatin3. Good healthBevacizumabRegimenchemistry030220 oncology & carcinogenesisQuality of LifeFemalebusinessOvarian cancermedicine.drug
researchProduct

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

2015

BACKGROUND: Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.METHODS: Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using…

Oncologymedicine.medical_specialtyDisease-Free SurvivalCholangiocarcinoma03 medical and health sciencesAdvanced diseaseCisplatin and gemcitabine0302 clinical medicineInternal medicinemedicineJournal ArticleHumansProgression-free survivalProportional Hazards ModelsPerformance statusReceiver operating characteristicManchester Cancer Research Centrebusiness.industryProportional hazards modelResearch Support Non-U.S. Gov'tResearchInstitutes_Networks_Beacons/mcrcHazard ratioArea under the curveCancerHematologymedicine.diseasePrognosisConfidence intervalSurgeryTreatment OutcomeOncologyBile Duct NeoplasmsROC Curve030220 oncology & carcinogenesisABC-02Multivariate AnalysisBiliary tract cancer030211 gastroenterology & hepatologybusinessPerformance statusPrognostic modelMeta-Analysis
researchProduct

Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.

2015

Background: PCA3 has been included in a nomogram outperforming previous clinical models for the prediction of any prostate cancer (PCa) and high grade PCa (HGPCa) at the initial prostate biopsy (IBx). Our objective is to validate such IBx-specific PCA3-based nomogram. We also aim to optimize the use of this nomogram in clinical practice through the definition of risk groups. Methods: Independent external validation. Clinical and biopsy data from a contemporary cohort of 401 men with the same inclusion criteria to those used to build up the reference’s nomogram in IBx. The predictive value of the nomogram was assessed by means of calibration curves and discrimination ability through the area…

PCA3MaleCancer Researchmedicine.medical_specialtyProstate biopsyBiopsyUrologyurologic and male genital diseasesRisk AssessmentDecision Support TechniquesCohort StudiesProstate cancerRisk groupsAntigens NeoplasmRisk FactorsGeneticsBiomarkers TumorMedicineHumansOpportunistic screeningAgedmedicine.diagnostic_testbusiness.industryArea under the curveExternal validationProstatic NeoplasmsOrgan SizeNomogramMiddle Agedmedicine.diseaseSurgeryNomogramsOncologybusinessBiomarkersResearch ArticleBMC cancer
researchProduct

Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis

2016

Purpose To investigate magnetization transfer ratio (MTR), T1 relaxation time, and proton density (PD) as indicators of gray matter damage in relapsing-remitting multiple sclerosis (RRMS), reflecting different aspects of microstructural damage and as imaging correlates of clinical disability. We aimed to determine which of these parameters may optimally quantify cortical damage, and serve as an imaging surrogate of clinical disability. In this study, cortical values of MTR, a surrogate for demyelination in MS, of PD, reflecting replacement of neural tissue by water, and of T1 , indicating a complex array of microstructural changes, were assessed in a group of RRMS patients in comparison to …

Pathologymedicine.medical_specialtyExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisArea under the curveMagnetic resonance imagingmedicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureRelapsing remittingCerebral cortexmedicineRadiology Nuclear Medicine and imagingMagnetization transferNuclear medicinebusinessProton density030217 neurology & neurosurgeryJournal of Magnetic Resonance Imaging
researchProduct

Metabolomic Profile of Human Myocardial Ischemia by Nuclear Magnetic Resonance Spectroscopy of Peripheral Blood Serum

2012

Objectives The aim of this study was to investigate the metabolomic profile of acute myocardial ischemia (MIS) using nuclear magnetic resonance spectroscopy of peripheral blood serum of swine and patients undergoing angioplasty balloon‐induced transient coronary occlusion. Background Biochemical detection of MIS is a major challenge. The validation of novel biosignatures is of utmost importance. Methods High-resolution nuclear magnetic resonance spectroscopy was used to profile 32 blood serum metabolites obtained (before and after controlled ischemia) from swine (n 9) and patients (n 20) undergoing transitory MIS in the setting of planned coronary angioplasty. Additionally, blood serum of c…

Pathologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentArea under the curveIschemiaInfarctionmedicine.diseaseChest painBlood serumCoronary occlusionInternal medicineAngioplastymedicineCardiologyBiomarker (medicine)medicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

Total plasma protein in very preterm babies: prognostic value and comparison with illness severity scores

2013

International audience; OBJECTIVE: We aimed to investigate the predictive value for severe adverse outcome of plasma protein measurements on day one of life in very preterm infants and to compare total plasma protein levels with the validated illness severity scores CRIB, CRIB-II, SNAP-II and SNAPPE-II, regarding their predictive ability for severe adverse outcome. METHODS: We analyzed a cohort of infants born at 24-31 weeks gestation, admitted to the tertiary intensive care unit of a university hospital over 10.5 years. The outcome measure was "severe adverse outcome" defined as death before discharge or severe neurological injury on cranial ultrasound. The adjusted odd ratio (aOR) and 95%…

PediatricsMultivariate analysisCritical Care and Emergency MedicineEpidemiology[ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/Pediatricslcsh:MedicinePediatricslaw.inventionCohort Studies0302 clinical medicinelawInfant Very Low Birth Weight030212 general & internal medicineProspective StudiesPediatric Epidemiologylcsh:ScienceMultidisciplinaryArea under the curveBlood ProteinsIntensive care unit3. Good healthCohortMedicineInfant PrematureResearch Articlemedicine.medical_specialtyPediatric Critical CareClinical Research DesignBirth weightFluid Management03 medical and health sciencesHypoproteinemia030225 pediatricsInternal medicinemedicineHumansPrematureRetrospective StudiesNutrition[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsReceiver operating characteristicbusiness.industryVery Low Birth Weightlcsh:RInfant NewbornInfantmedicine.diseaseNewbornConfidence intervallcsh:QNeonatologybusiness
researchProduct

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

2019

Introduction: Prevention of haemophilic arthropathy and quality of life´s (QoL) improvement are still the main goals in the haemophilia community. Haemophilic arthropathy is the result of clinical and subclinical bleeding during everyday activities and/or traumatic situations. Prophylaxis with extended half-life (EHL) factor replacement therapy is understood as an improvement solution for factor VIII (FVIII) PK properties, as half-life (T1/2) and area under the curve (AUC), however few real world data are yet available. EHL improved pharmacokinetic (PK) properties might directly drive into a reduction of the bleeding risk during physical activity (both therapeutical or leisure) for a longer…

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyArea under the curveCell BiologyHematologyHemarthrosismedicine.diseaseHaemophiliaBiochemistryHemophiliasDiabetes mellitusmedicineAnxietyTrough levelmedicine.symptombusinessDepression (differential diagnoses)Blood
researchProduct

Modelo predictivo preliminar para la identificación de pacientes con oportunidades de mejora farmacoterapéutica

2010

Objective: To develop a prediction model for identifying patients with the possibility of improving pharmacotherapy during the process of pharmaceutical validation of the prescription. Method: Cross-sectional study over two months, performed in the Internal Medicine and Infectious Disease divisions. Detecting opportunities for improving quality of pharmaco¬therapy is done by means of a pharmacist's validation of the prescription. Based on the information we obtained through this process, we performed a multivariate logistic regression analysis using as prognostic factors the demographic, pharmacotherapy and clinical variables related to identifying any drug-related problems (DRPs) in the pa…

PharmacologyGerontologymedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationPharmacistArea under the curveLogistic regressionPharmacotherapyInternal medicinemedicineDosage adjustmentPredictive variablesMedical prescriptioneducationbusinessFarmacia Hospitalaria
researchProduct